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Objective: To explore which attributes of insulin therapy drive patients’ preferences for 
management in Canada and Brazil. 
Methods: A qualitative design was implemented in which a total of 32 patients with type 2 
diabetes from Canada and Brazil, were interviewed in one of the 4 focus groups, or 16 individual 
interviews. Eighteen participants (56%) were women and fourteen participants (44%) were men 
(15 insulin nonusers and 17 insulin users). Two focus groups of 4 participants each and 9 indi-
vidual interviews were conducted in Brazil. In Canada, 2 focus groups of 4 participants each and 
7 individual interviews were conducted. A framework analysis was used to analyse all data. 
Results: Brazilian participants, when considering two insulin treatments, would prefer the one 
that had fewer side-effects (specially hypoglycemia events), was noninjectable, had the lowest 
cost and was most effective. Meanwhile, Canadian participants would prefer a treatment that 
had fewer side-effects (specially weight gain), was less invasive, was more convenient and was 
most effective. 
Conclusions: Finding the insulin-delivery system and the attributes of insulin therapy that best 
meet patients’ preferences may lead to improved control, through improved compliance, which 
may ultimately reduce the financial burden of the disease and improve quality of life.
Keywords: type 2 diabetes, insulin administration, glycemic control, weight gain, hypoglycemia, 
qualitative study, patients’ preferences
Introduction
Diabetes mellitus is one of the most common noncommunicable diseases globally, and 
exerts a substantial burden on patients, society and the health care system. Approxi-
mately 1 million (4.8%) Canadians aged 20 years and older had diabetes in 1998/99,1 
and this number is expected to increase to 2.4 million patients in 2016.2 Therefore, if 
the prevalence of diabetes follows current trends, health care costs for people with dia-
betes in Canada will increase by 75% between 2000 and 2016.2 Currently, 4.6 million 
people have diabetes in Brazil and if nothing is done to slow this epidemic, this number 
is expected to exceed 11.3 million by 2030.3 Therefore, the resulting diabetes related 
morbidity and mortality will continue to pose an economic burden worldwide.3,4
Many of the complications and their associated costs attributable to diabetes are pre-
ventable. Increasing the effectiveness of surveillance and treatment for those who have 
the disease has been shown to be effective in decreasing long-term costs as a result of 
delayed or prevented complications.4 Improved blood-glucose control remains the goal of 
therapy for patients in order to prevent the development of diabetes complications that can 
substantially impact patients’ longevity and quality of life, and increase health care costs.  Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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Despite advances in development of insulin analogs that has 
greatly improved the clinical effectiveness of insulin therapy, the 
goal of improved blood-glucose control remains elusive as many 
patients are either not using subcutaneous insulin therapy at all, 
or are noncompliant.5 Lack of diabetes education, inconvenience 
of repeated daily injections, fear of needles, injection-related 
anxiety, denial, and feeling that the disease has progressed are 
often major contributing factors.6–10 In this context, patients may 
be more likely to initiate insulin therapy if an alternative to the 
injectable route was available.9
Alternative routes of insulin delivery that are more clini-
cally effective, more tolerable, and physiologically more like 
endogenous insulin are continously being investigated. The 
two most clinically promising options to date are oral and 
pulmonary insulin delivery system. Researchers have tried 
several approaches to overcome gastrointestinal metabolism 
and promote the bioavailability of oral insulin. The most prom-
ising oral insulin to date is hexyl-insulin-monoconjugate-2 
(HIM-2), a recombinant insulin that has alterations in physio-
chemical characteristics that resist enzymatic degradation and 
facilitate absorption. Preclinical safety and pharmacokinetic 
data for HIM-2 are beginning to emerge and ongoing phase I 
and II clinical trials suggest that it may produce an acceptable 
glucose-lowering effect. In addition, because oral HIM-2 is 
delivered to the liver through the portal circulation thereby 
reproducing the physiological route of insulin secretion, oral 
HIM-2 may result in avoidance of pheripheral hyperinsuline-
mia.11 Pulmonary delivery of insulin is feasible given the large 
surface area and high permeability of the lungs where insulin 
can be effectively absorbed via the pulmonary alveoli.12 How-
ever, the inhalable insulin, Exubera®, approved for use in 2006 
as the first available alternative to insulin injections, was taken 
off the market less than two years later due to limited adoption 
by patients. Barriers may have been the cumbersome delivery 
system, safety concerns, and cost of the therapy, but this has 
not been explored. Attempts to overcome these problems have 
been made by other companies that are developing their own 
versions of inhaled insulin and promising results regarding 
patients’ acceptance are beginning to emerge.13
The traditional approach to the physician-patient relation-
ship in medical care, which focuses on disease rather than 
the patient, is usually ineffective in assisting patients to ade-
quately manage their chronic illness. A partnership between 
the patient and physician is a model of patient-centred care 
that points at the importance of patients’ participation in the 
decision-making process, and has been shown to increase 
adherence to management protocols, reduce morbidity, and 
improve quality of life of the patients with chronic disease.14 
In addition, because diabetes is a self-managed disease, for 
diabetes care to succeed patients must be able to make deci-
sions about how they will live with their illness.15 For health 
care providers to sucessfully facilitate patients’ compliance 
which in turn will lead to increased effectiveness and less 
burden of disease, they will need to incorporate patients’ 
preferences into diabetes treatment decision-making.16,17 
Although the importance of the concordance model has been 
recognized in the literature18 and studies are emerging on 
patients’ perceptions of diabetes therapy,16–19 formal valuation 
and quantification of patient’s preferences for insulin therapy, 
and how they may be willing to trade off different attributes 
of insulin therapy, remains scarce.
The health care system, access to specific types of health 
care and drug therapy, and individual experiences with how 
they receive care for their chronic diseases is likely to influ-
ence patients’ preferences for different aspects of therapy. 
Thus, we sought to elicit patients’ preferences for insulin 
management of diabetes in two countries with very different 
health care systems, access to medications, and diabetes-
related outcomes. For example, in Brazil the public health 
care system does not cover all available drug therapies. For 
diabetic patients, it only covers some oral medication, NPH 
and regular insulins, glucose testing strips, and vials and 
syringes. Otherwise, other insulin devices (ie, pens, pump) as 
well as other insulins (ie, lantus, detemir) are available mainly 
for those who can afford to buy them, which means that most 
Brazilians use vials and syringes. Conversely, in Canada 
medical insurance coverage generally includes the costs of 
most therapies. In terms of insulin therapy, Canada and Brazil 
differ significantly in that insulin therapy in Canada primarily 
involves insulin pens compared to Brazil where insulin treat-
ment still entails the use of needles, syringes, and multidose 
insulin vials. For these and other reasons it was therefore 
felt that patients with diabetes could potentially have differ-
ent preferences for insulin therapy. One Canadian study has 
attempted to quantify patients willingness to pay for inhaled 
insulin using a contingent valuation methodology,20 while in 
Brazil no study has been identified. Therefore, the purpose of 
this study was to understand and compare which attributes of 
insulin therapy drive patients’ preferences for management 
in both Canada and Brazil. The results of this study will then 
be used to quantify patients’ preferences for insulin therapy, 
and to determine the relative importance that patients with 
type 2 diabetes place on different treatment attributes, using 
a discrete choice experiment (DCE).
Methods
A qualitative descriptive design was used in which focus 
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from patients with type 2 diabetes. The practice of qualitative 
analysis is based upon two assumptions. The first is episte-
mological and states that qualitative researchers “believe 
that a phenomenon should be viewed in context”,21 meaning 
that a researcher should be gathering knowledge/experiences 
from stakeholders in their own words. The second assump-
tion is ontological and suggests that “there is not a single [all 
encompassing] reality apart from our perceptions”,21 which 
suggests that to have an understanding of the impression of 
insulin use among type 2 diabetics, it is important to gather 
their words and ideas from them. With respect to this study 
specifically, the importance of these assumptions necessitated 
speaking directly with people with type 2 diabetes to begin to 
understand their views and perceptions of insulin therapy.
Focus group and individual interviews are becoming 
increasingly popular in health research for involving individu-
als in care management, treatment decision-making process, 
needs assessment, and health promotion.22,23 Focus group 
methodology is a form of group interview that capitalizes on 
interaction between research participants in order to explore 
the issues of importance to them based on each others’ experi-
ences and point of view, and pursuing their own priorities.23,24 
In contrast, individual interviews are guided, one-to-one 
sessions. Therefore, both methods facilitate understanding 
participants’ perceptions that may be helpful in identifying 
variables and hypotheses for quantitative research. However, 
these two methods are not substitutes but rather complemen-
tary.25 Because of that, both methods were used to provide 
complementary information leading to the identification of 
the most important attributes of insulin therapy, including 
the potential risks and benefits, that drive patients’ treatment 
preferences, using their own vocabulary.
Ethics approval was obtained from both University of 
British Columbia-Providence Health Care Research   Ethics 
Board and University of São Paulo Ethics Committee. 
  Participants were asked to sign a written informed consent 
for study entry.
recruitment and data collection
Focus group and individual interviews were conducted in 
both Canada and Brazil. A random sample was composed 
of type 2 diabetic men and women who attended a local 
diabetes education clinic at St Paul’s Hospital in Vancouver, 
B.C, Canada, and a local hospital in Ribeirão Preto, 
São Paulo, Brazil. Patients were eligible for enrolment if 
they were 19 years of age or older, had physician-diagnosed 
type 2 diabetes, and were being actively treated with either 
an oral hypoglycemic, insulin, or both. The recruiting strat-
egy included a personal approach involving an explanation 
of the study to potential participants by a member of the 
research team (CG) as well as using recruitment posters. In 
B.C, Canada, all patients are required to attend a diabetes 
education program before the costs of their glucose testing 
strips will be covered. In Ribeirão Preto, Brazil, all patients 
are required to be registered in the public heath care system 
before they are given their glucose testing strips without any 
costs. Therefore, participants in this study are expected to be 
representative of all type 2 diabetics.
An initial discussion guide was designed to help to create 
an open enviroment, and to facilitate the successful comple-
tion of the interviews by collecting as much information as 
possible regarding patients’ perceptions of insulin therapy. The 
moderator used the same interviewer guide to conduct the focus 
groups and individual interviews in both countries. Initially, 
the moderator briefly gave baseline information regarding 
insulin therapy and potential alternatives for the subcutaneous 
route so all patients would have a similar baseline knowledge 
regarding the issues to be discussed. The moderator encouraged 
discussion of the widest possible range of attributes associated 
with insulin therapy with open ended questions supplemented 
with follow-up questions following some discussion. Both the 
focus groups and individual interviews were conducted in the 
same place patients were recruited, and typically lasted 30–50 
minutes. All individual interviews and focus groups were audio 
recorded, transcribed and analyzed.
Given that many diabetes treatment options are asso-
caited with both potential risk and benefits, issues for 
  discussion raised by the moderator included the pros 
(benefits) and cons (risk) of insulin therapy such as poten-
tial side effects of diabetes oral medication and insulin, 
emotional problems associated with insulin use or starting 
insulin treatment, cost of diabetes treatment, convenience 
of insulin administration, dislikes of diabetes medication, 
concerns about starting insulin treatment, alternative routes 
for insulin administration and the most important attributes 
of insulin therapy. All focus groups were composed of either 
insulin users or insulin nonusers because we hypothesized 
a priori that patients in each group would have different 
experiences and perceptions. Because of this difference, not 
all the issues were discussed in each group. Data collection 
continued until no new information resulted from the focus 
group and individual interviews, and it was deemed that all 
major themes were saturated.26
Data analysis
A framework analysis was used to analyse all data.27 Study 
data included notes from the moderator and participants, and 
the audio files and the transcripts from both individual and  Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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focus group interviews. The process of data analysis began 
during the data collection, by facilitating the discussion in 
order to generate the richest data possible. This provided a 
complete record of the interviews and facilitated analysis of 
the data.28 The familiarization with the data was achieved by 
listening to the audio recorded files and reading the transcripts 
as well as the moderator and particpants’ notes several times 
to get a sense of each interview as a whole before breaking 
it into parts. Ideas, notes and short sentences that arose from 
the transcripts were written in the margin of the pages and 
the major themes begun to emerge. Relevant quotes were 
also highlighted in the transcripts.
All relevant quotes, ideas and notes that arose from the 
data were then re-arranged under the newly developed main 
themes. This was to achieve data reduction by putting relevant 
information together and deleting data that did not relate 
to insulin therapy. Each participant was asked to answer a 
final summary question in which he/she should list the most 
important atrributes of the insulin treatment for them, in 
order of importance, taking into account everything that was 
discussed in the interview. These follow up probes were also 
analysed by the researchers to consider the consistency and 
the specificity of responses. In addition, for interpreting the 
data, words, context, internal consistency, the frequency and 
extensiveness of comments were also considered.24
Results
A total of 32 patients with type 2 diabetes from both countries 
were interviewed in one of the 4 focus groups or 16 individual 
interviews. Eighteen participants (56%) were women, and 15 
(47%) were insulin naïve. Two focus groups of 4 participants 
each and 9 individual interviews were conducted in Brazil. In 
Canada, 2 focus groups of 4 participants each and 7 individual 
interviews were conducted. The mean age of the sample was 
58, ranging from 32 to 85 years. In both countries, similar 
themes emerged from the interviews. Major themes identified 
that drive patients’ preferences for management included side-
effects, effectiveness and cost of insulin therapy. Participants 
also seek treatment approaches that allow the elimination of 
injections, particularly in   Brazil. In Canada, convenience 
was another important theme for patients. Table 1 shows a 
summary of the main results.
side effects
The theme of side effects reflected participants’ desire to 
experience fewer hypoglycemic events and less weight 
gain. However, hypoglycemia appeared to be more dis-
turbing for Brazilians, while weight gain emerged more 
frequently among Canadians. In Brazil, the importance of 
hypoglycemia events can be illustrated by the comments 
of two participants: “I take insulin three times a day an I 
still can not have my blood sugar controlled, I have many 
events of hypoglycemia and it is very disturbing”. 59-year 
old female, insulin user. Another stated, “I have been much 
more controlled after I started with insulin, and my biggest 
complaint today is the hypoglycemia events I have during 
the night”. 31-year-old male, insulin user. Hypoglycemic 
events were also important for the insulin naïve as can 
be illustrated by the comment of one participant: “I am 
feeling good, without any hypoglycemia or hyperglycemia 
events, there is no need for me to use insulin”. 61-year-old 
female.
In Canada, the comments of many participants illustrate 
patient’s desire to avoid weight gain: “I would have to agree 
that the weight gain is one of the factors I didn’t like about 
insulin. That normal weight gain is an issue”. 53-year-old 
male, insulin user. Another participant stated: “Weight gain is 
of course the worst side effect. And that’s been an emotional 
problem”. 50-year-old male, insulin user. Another participant 
said: “I do experience weight gain, from the insulin itself. 
That is uncomfortable, I don’t like that feeling. I’d rather 
be on a pill, rather than the insulin, for that weight gain 
factor”. 46-year-old female, insulin user. In addition to the 
weight gain, hypoglycemia emerged as another disturbing 
side effect: “If I have one immediate fear of diabetes, it’s 
hypoglycemia”. 69-year-old-female, insulin-naïve. Another 
said: “I do experience hypoglycemia, maybe once or twice 
a month. Um, that’s really uncomfortable”. 46-year-old 
female, insulin user.
Avoidance of injections
A strong desire to avoid injections was the most frequent 
issue raised by Brazilian participants when asked what they 
believe would be important for them when it comes to insulin 
therapy. Many insulin naïve spoke about their fear of injec-
tions: “There is no way I will start insulin, I can not inject 
myself, I feel terrified just to think about the injections”. 
62-year-old male. Another stated, “I do not feel just fear of 
the injections, I feel terrified of them”. 58-year-old female. 
Interestingly, some insulin users shared the same opinion 
as illustrated by this comment, “I take insulin twice a day 
but I just can not inject myself, I have fear of the   injections 
and my friend’s husband is the one who injects for me”. 
64-year-old female. Another stated, “I am better controlled 
with insulin, but I simply hate the injections, I wish I could 
get rid of them”. 58-year-old male. For those taking insulin, 
when asked about their dislikes of insulin therapy, they also 
spoke about the pain and body injuries associated with the Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
175
Patients’ perceptions for insulin therapy in canada and Brazil
Table 1 Major themes identified that drive patients’ preferences for insulin therapy
Side-effects
“I have been much more controlled after I started with insulin, and my biggest complaint today is the hypoglycaemia events I have during the night”.
31-year-old Brazilian male
“I do experience weight gain, from the insulin itself. That is uncomfortable, I don’t like that feeling. I’d rather be on a pill, rather than the insulin, for that weight 
gain factor.” 
46-year-old canadian female
Avoid injections
“I am better controlled with insulin, but I simply hate the injections, I wish I could get rid of them.” 
58-year-old Brazilian male
“I would do the impossible to avoid the injections, they are very inconvenient and because I am not very careful with changing the local of the injections, I am 
usually full of hard spots.” 
58-year-old Brazilian male
“If a pill was available it would improve a lot my life, I hate the injections, they are like a bad kharma in my life.” 
33-year-old Brazilian female
“If I lose control, where I’m forced to take insulin, then I’m gonna look at the alternatives of how I’m gonna take it. What I’m saying is I don’t wanna shoot myself 
if there’s something that I could just breathe it in.” 
48-year-old canadian male
Effectiveness
“I have been much better controlled after I started insulin I feel less thirsty and in a better mood, but there’s no way I like the injections.” 
64-year-old Brazilian female
“I guess the most important thing for me is the control of my blood sugars and what goes with that. That you’re feeling better, that I’m not running to the 
bathroom to pee. And, it improves your quality of life.” 
50-year-old canadian male
“I take insulin because I fear the complications of my diabetes, and I know the insulin can help me to avoid them.” 
42-year-old Brazilian female
Cost
“In order to be a healthier person, if it means taking insulin I’ll take the insulin, but I’m gonna search high and low, for the most practical and least invasive means 
of accepting it. I don’t care about the cost. It could cost me half of my salary.”
48-year-old canadian male 
“If I have to pay extra I would continue with the injections because I can’t afford extra expense, but if a pill was covered from the government the same way my 
injections are, of course I would prefer the pill.” 
58-year-old Brazilian male 
“If a pill was available I would do what I could to buy it because I take insulin three times a day and it is very uncomfortable, it hurts.” 
42-year-old Brazilian female
Convenience
“Well, I take my insulin 5 times a day. So, it is inconvenient if I’m out somewhere shopping, and stuff like that. And sometimes I just get tired of doing it. It’s a lot 
of extra work.”
55-year-old canadian female
“What I don’t like is having to stick to that strict regiment of taking it early in the morning, and having breakfast, and then having to take it at 5 o’clock, and 
having supper. More convenience, not having such a regimented schedule would be nice.” 
46-year-old canadian female
“I’m doing my best to take my insulin on time, every day. But sometimes I do forget, and sometimes I’m not home, at the right time to do my insulin. It cause 
some inconvenience sometimes, specially when I travel. You know, I can’t be on time for my insulin, and it’s a trouble, even the transportation sometimes.” 
72-year-old canadian male
injections: “I take insulin three times a day and I feel the 
pain very inconvenient”. 42-year-old female. Another said, 
“I would do the impossible to avoid the injections, they are 
very inconvenient and because I am not very careful with 
changing the local of the injections, I am usually full of hard 
spots”. 58-year-old male. There was a strong and consistent 
preference for an oral insulin formulation to make the 
treatment more convenient and particularly to eliminate the 
injections: “A pill would be much better. It would facilitate 
a lot my life”. 31-year-old male. Another said, “If a pill was 
available it would improve a lot my life. I hate the injections, 
they are like a bad karma in my life”. 33-year-old female. Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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In Canada, concerns and dislikes related to insulin 
therapy included fear of the needles as well as the pain and 
body injuries associated with the injections: “The part of 
my insulin treatment I don’t like, of course, is stickin’ myself 
with needles. Sometimes it hurts when you give yourself an 
injection. I would like to get off it, but we are heading that 
direction”. 59-year-old man, insulin user. Another participant 
said: “I don’t want to take insulin mainly because I am a 
little bit scared about needles”. 70-year-old female. Another 
stated: “The only thing that I dislike is the bruising. That 
you would see the marks. And that people go, ‘What’s that 
on you?’”. 50-year-old male. Many patients also showed a 
strong desire for another route of administration to avoid 
injections: “If I lose control, where I’m forced to take insulin, 
then I’m gonna look at the alternatives of how I’m gonna take 
it. What I’m saying is I don’t wanna shoot myself if there’s 
something that I could just breathe it in”. 48-year-old male. 
Another participant said: “If they can find something that 
could eliminate the injections. It will be great if they can 
find an oral insulin, that you just swallow, and, you know, 
that would be great”. 63-year-old man, insulin user. Another 
participant said: “I never liked the needles, it cause me a little 
bit of pain. I really don’t like it. Well, I hope that something 
can replace insulin in the future, and so, that I don’t have to 
have injections. Something like oral would be even better, 
because at least I can’t feel that needle pain”. 72-year-old 
male, insulin user.
effectiveness
In both countries, the theme of effectiveness reflected 
patients’ improvement in well being with insulin therapy as 
well as patients’ awareness of the benefits of insulin treatment. 
In addition, some Brazilians also stated that they take insulin 
because they fear the complication of their diabetes.
In Brazil, many of the insulin users stated that they do not 
like the injections but they stand it because they feel better 
when they take insulin: “I have been much better controlled 
after I started insulin, that’s why I take it, I feel less thirsty 
and in a better mood, but there’s no way I like the injec-
tions”. 64-year-old female. Another stated, “I take insuln just 
because it helps me to decrease my blood sugar and then I 
feel better”. 58-year-old male. Some participants stated that 
they take insulin because they fear the complication of their 
diabetes: “I take insulin because I had heart problems and I 
fear the complications of my diabetes, and I know insulin can 
help me to avoid them”. 42-year-old female. Another said, 
“The main reason I take insulin is because it’s what keeps 
me alive, and if I don’t take it, my diabetes will complicate 
and I don’t want that”. 31-year-old male.
In Canada, the importance of effectiveness can also be 
illustrated by the following comment: “The most important 
thing is getting the blood sugar down to the ideal level”. 
53-year-old Canadian male. Some patients, similarly to the 
Brazilian patients, associated the blood glucose control with 
an improvement in well being, as one participant stated: 
“I guess the most important thing for me is the control of 
my blood sugars and what goes with that. That I’m feeling 
better, that I’m not running to the bathroom to pee, and all 
these things. I’m in control, I’m feeling better, there’s noth-
ing better than that. And, it improves your quality of life, so 
getting better control makes a big difference”. 50-year-old 
male, insulin user.
cost
Many participants had no out-of-pocket expenses related to 
their diabetes medication treatment at the time of the study. 
However, despite this, cost emerged as one of the most impor-
tant attributes related to the insulin therapy in both countries, 
although in different ways. In Brazil, although patients’ desire 
to avoid injections, have less side-effects, and for an alter-
native and more convenient route of insulin administration, 
many participants were not willing to pay out-of-pocket for 
them. The comments of two participants clearly reveal the 
problem: “If I have to pay extra I would continue with the 
injections because I can’t afford extra expenses, but if a pill 
was available with no costs the same way my injections are, 
of course I would prefer the pill”. LCP, 58-year-old male. 
The participants that were willing to pay out-of-pocket stated 
that they would pay for an oral route: “If a pill was available 
I would do what I could to buy it because I take insulin three 
times a day and it is very unconfortable, it hurts”. MLNP, 
42-year-old female.
When the Canadian patients were asked if they would be 
willing to pay extra for any of the insulin therapy attributes, 
they said that they were willing to pay out-of-pocket for an 
alternative route to eliminate injections, for improved conve-
nience, to feel better. One participant said: “If my condition 
was to deteriorate, I would be willing to pay more to feel 
good”. MAP, 69-year-old female, insulin naïve. Another 
stated: “I would be willing to pay more for improved con-
venience”. GHT, 50-year-old male, insulin user. Another 
participant said: “I think paying more would justify having 
more convenience, definitely”. SEMB, 46-year-old female, 
insulin user. Among the insulin naïve participants, some 
said that they would not have a problem taking insulin, but 
they would prefer the more convenient way as possible: “In 
order to be a healthier person, if it means taking insulin I’ll 
take insulin, but I’m gonna search high and low, for the most Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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practical and least invasive means of accepting it. I don’t 
care about the cost. It could cost me half of my salary”. RAY, 
48-year-old male.
convenience
In Canada, many insulin users raised the inconvenience 
of using insulin when asked about their dislikes related to 
the insulin therapy. Many patients spoke about the incon-
venience in public places, the strict schedule, the inconve-
nience when travelling, and the frequency of administration: 
“Well, I take my insulin 5 times a day. So, it is inconvenient 
if I’m out somewhere shopping, and stuff like that. And 
sometimes I just get tired of doing it. It’s a lot of extra 
work”. MAG, 55-year-old female. Another stated: “For 
me, what I don’t like about insulin is the inconvenience. 
Having to stick to that strict regiment of taking it early in 
the morning, and having breakfast, and then having to take 
it at 5 o’clock, and having supper. I don’t like that strict 
regiment. That’s about the biggest thing for me. More con-
venience, not having such a regimented schedule would be 
nice”. SEMB, 46-year-old female. Another participant said: 
“I’m doing my best to take my insulin on time, every day. 
But sometimes I do forget, and sometimes I’m not home, 
at the right time to do my insulin. It causes some inconve-
nience sometimes, specially when I travel. You know, I can 
not be on time for my   insulin, and it’s a trouble, even the 
transportation sometimes”. JK, 72-year-old male. Another 
stated: “Like when I go to a party, or gathering, I have to 
go to a certain place, or even in front of the public, open 
up my shirt, and do the insulin, and, I didn’t like to do it, 
those kind of things like the insulin with the public, but 
sometimes I have no choice, and there is no place to go to 
do it”. JM, 63-year-old male.
Discussion
Individual and focus group interviews proved to be efficient 
techniques of exploring patients’ perceptions of insulin 
therapy among type 2 diabetics. Overall, participants from 
both countries identified similar attributes as major con-
tributors to their preferences in regards to insulin therapy. In 
general, when considering insulin treatments, patients in this 
study would prefer a treatment with the fewest side-effects 
(in particular, weight gain and hypoglycemic events), does 
not require injection, and is the least costly and the most 
effective. In Canada, convenience was another major theme 
that emerged from the interviews. Brazilian participants 
were more emphatic on avoidance of injections compared 
to Canadians. These findings are in accordance with previ-
ous studies that have shown that treatment preferences for 
insulin therapy seem to be largely based on the side-effects, 
effectiveness, convenience and cost.20, 29–31
Some basic background information regarding insulin 
therapy and alternative routes of insulin administration was 
provided to all participants at the beginning of all interviews 
to ensure that all participants had the same baseline knowl-
edge regarding the issues of interest. Interestingly, the major-
ity of insulin users from both countries were not aware of 
the potential alternative routes of insulin administration and 
most insulin naïve patients had very little general knowledge 
of insulin therapy in general. Some participants did not even 
understand that diabetes is a progressive disease and that 
insulin use is likely in their future: “I am well controlled 
and hopefully I will never need the injections, I fear them”. 
NLC, 72-year-old Brazilian female. Another said: “If you’re 
gone to number 2 diabetes, what are the chances that you 
will have to take insulin, eventually?” MOB, 85-year-old 
Canadian female.
In addition to the main themes that emerged from the 
interviews, Canadian participants also reported some kind of 
emotional problem related to their treatment such as feelings of 
failure, guilt, feelings that the disease had progressed, and fear 
of the complications of the disease. These findings support the 
idea that diabetes treatment is a psychological burden for many 
patients.6,32,33 In addition, many patients from both countries 
also believed insulin to be the last resort to manage diabetes, 
and they associated insulin with the progression of the desease: 
“But with type 2 diabetes I feel I’m early in the disease, and 
there’s not that sense of urgency and fear. Whereas, if I start to 
take insulin, then I realize, I’m getting closer to the end. I’m 
just hoping that I don’t get that far. ” RP, 47-year-old Canadian 
male. This finding is in accordance with previous studies,6,8 
and may help to understand why many patients either delay 
or refuse to start insulin therapy if at all possible.
Some Canadians, particularly the elderly participants, 
reported concerns related to aging when considering initiating 
insulin use: “Withdrawing insulin from the bottle, even get-
ting the needle into the bottle. So that would be a concern 
for me. The older I get, the less mentally acute I become”. 
MAP, 69-year-old female. Another stated: “I hope I don’t go 
into insulin, because I notice as I grow older, I’m 85, that 
my hands get shaky, and I’ve also lost the strength in my 
hands”. MOB, 85-year-old female. This finding suggests 
that an alternative route of administration may benefit many 
patients that feel they are unable to self-inject.
Participants from both countries showed a strong desire to 
avoid the injections, however, Brazilians appeared to me more 
emphatic, when compared to Canadians. This may be explained 
by the fact that most of the Brazilian participants were using  Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
Dovepress 
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vials and syringes at the time of the study, while most of the 
Canadians were using insulin pens, which have been shown 
to be less painful and more convenient:34 “When I first had to 
use the syringes, I didn’t like that at all. I felt ashamed to use 
that. I felt like a drug addict or something. So I find the pen 
much more acceptable”. MAG, 55-year-old female.
Another issue frequently raised by participants from both 
countries was a strong desire for an oral route, specially to 
make the treatment more convenient and to eliminate injec-
tions. Many Canadians said that they were willing to pay out-
of-pocket for an alternative route, for more convenience, and 
to eliminate injections. On the other hand, although Brazilians’ 
preferred to avoid injections experience fewer side-effects, 
most were not willing to pay out-of-pocket for them. The few 
Brazilian participants that were willing to pay out-of-pocket 
stated that they would pay for an oral route for insulin admin-
istration. Despite this strong desirability to avoid injections, 
it is interesting to note that many patients agreed that insulin 
therapy is the best treatment to achieve blood glucose control. 
This finding has been reported elsewhere.19
In general, patients from both countries showed an overall 
dislike for the insulin therapy and the most raised reasons 
were: the rigid schedule and inconvient time and frequency 
of administration, the pain and body injuries associated 
with the injections, the inconvenience in public places, the 
fear of injections, feelings that the disease had progressed, 
and the weight gain and higher frequency of hypoglycemia. 
Brazilian patients also reported that health providers paid 
little attention to their concerns regarding diabetes treatment. 
However, if measures are to be taken to improve compliance, 
these should be based on a deeper understanding of patient’s 
experiences of their treatment rather than the perceptions of 
health care providers.18
A large ongoing North American trial of diabetes, called 
ACCORD, designed to intensively lower blood glucose 
of adults with type 2 diabetes at high risk of heart disease 
has been halted because of an increased number of deaths 
among those receiving intensive treatment compared to those 
receiving less-intensive standard treatment. This finding was 
unexpected as it is well established that an HbA1c goal of 
less than seven percent reduces microvascular complications 
resulting from diabetes. Researchers have not determined 
a specific cause for the increased deaths among the inten-
sive treatment group, but the results from ACCORD study 
strengthen the importance the individualization of treatment 
to determine what the treatment goals should be for a specific 
patient with specific characteristics.35 Therefore, for health 
care providers to facilitate improved diabetes management 
and treatment adherence, which in turn is expected to improve 
treatment effectiveness, reduce long term complications and 
improve patient outcomes, they will need to incorporate 
patients’ preferences into their decisions in regards to dia-
betes management.16,17
Now that we have identified the most important attri-
butes of the insulin therapy from patients’ perspectives in 
both countries, we will move forward to quantify the value 
patients place on each attribute, in monetary terms, and the 
rate at which they would be willing to accept trade-offs 
among insulin therapy attributes. This ongoing study will 
be, to the best of our knowledge, the first discrete choice 
experiment (DCE) to simultaneously quantify the cost-utility 
of   different attributes of insulin therapy such as effectiveness, 
side-effects, convenience and route of administration.
Conclusions
Although the relationship between medication adherence and 
health outcomes is complex, our findings suggest that open 
and ongoing discussions that addresses patients’ concerns 
regarding potential side-effects, effectiveness, convenience, 
route of administration, and potential cost of insulin therapy 
need to be considered, particularly when trying to initiate 
insulin therapy. In particular, we found that an alternative to 
the injectable insulin may mitigate some of the resistance to 
initiating insulin therapy and improve treatment adherence for 
many patients These findings, in conjunction with the removal 
of Exubera® from the market, further emphasize the need 
for continued investigation of alternative insulin-delivery 
systems that will better meet the needs and preferences of 
patients. In addition, we also determined patients’ prefer-
ences for insulin therapy to be largely based on effective-
ness, convenience, route of administration, side-effects and 
cost. Therefore, finding the insulin-delivery system and the 
attributes of insulin therapy that are constitent with patients’ 
preferences may lead to improved control, through improved 
treatment adherence, which may ultimately reduce the finan-
cial burden of the disease and improve quality of life.
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